CORDRAN SP
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CORDRAN SP (CORDRAN SP).
Topical corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), inhibiting arachidonic acid release and subsequent prostaglandin and leukotriene synthesis, thereby mediating anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Minimal systemic absorption; metabolized primarily in the liver via CYP450 enzymes with renal excretion of metabolites. |
| Excretion | Primarily renal as inactive metabolites; <5% unchanged. Minimal biliary/fecal elimination. |
| Half-life | Terminal half-life approximately 48 hours; prolonged with hepatic impairment. |
| Protein binding | >90% bound to albumin and corticosteroid-binding globulin. |
| Volume of Distribution | Vd approximately 0.5 L/kg; indicates extensive tissue distribution. |
| Bioavailability | Topical: low systemic absorption (approximately 1–5% across intact skin). |
| Onset of Action | Topical: hours to days for anti-inflammatory effect. |
| Duration of Action | Duration 12–24 hours after single topical application; prolonged with repeated use. |
| Molecular Weight | 436.5 |
Apply a thin film to the affected area 1 to 2 times daily. Use the smallest amount for adequate therapy. Do not use for more than 2 weeks per course of treatment.
| Dosage form | CREAM |
| Renal impairment | No dosage adjustment required. |
| Liver impairment | No dosage adjustment required. |
| Pediatric use | Apply a thin film to the affected area 1 to 2 times daily. Use the smallest amount for adequate therapy. Do not use for more than 2 weeks. Caution: avoid prolonged use, occlusion, and application to large surface areas due to increased systemic absorption. |
| Geriatric use | Use with caution; apply a thin film to the affected area 1 to 2 times daily. Use the smallest amount for the shortest duration due to increased risk of skin atrophy and systemic effects. |
| 1st trimester | Corticosteroids are generally avoided in the first trimester due to risk of orofacial clefts. Use only if benefits outweigh risks; consider non-halogenated alternatives. |
| 2nd trimester | Limited data but systemic absorption from topical use is minimal; however, prolonged use or large areas may cause fetal growth restriction. Use lowest potency for shortest duration. |
| 3rd trimester | May be used with caution; avoid prolonged treatment near term due to risk of neonatal adrenal suppression. |
Clinical note
Comprehensive clinical and safety monograph for CORDRAN SP (CORDRAN SP).
| Placental transfer | Minimal systemic absorption from topical application; however, if absorbed, corticosteroids cross the placenta and can affect fetal adrenal function. |
| Breastfeeding | Topical flurandrenolide is minimally absorbed systemically; however, avoid application to breasts or large areas to reduce infant exposure. Use lowest potency and shortest duration. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to flurandrenolide or any componentUntreated bacterial, fungal, or viral skin infectionsOcclusive dressings over large areas
| Precautions | Systemic absorption may cause reversible HPA axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria., Use in children may cause more significant HPA axis suppression due to higher skin surface-to-body weight ratio., Avoid use on face, axillae, or groin unless directed by physician., Do not use with occlusive dressings unless directed., Discontinue if irritation develops. |
| Food/Dietary | No known food interactions with topical flurandrenolide. No dietary restrictions required. |
Loading safety data…
| Lactation Rating | L3 |
| Teratogenic Risk | Topical corticosteroids, including flurandrenolide, have been associated with low birth weight and orofacial clefts in animal studies at high systemic doses. In humans, topical use during pregnancy is not expected to result in significant systemic absorption, but prolonged or widespread use may increase risk. First trimester: No adequate human data; avoid if possible. Second and third trimesters: Use lowest potency for shortest duration; known fetal risks include intrauterine growth restriction with chronic high-dose exposure. |
| Fetal Monitoring | Monitor for signs of systemic corticosteroid effects (e.g., hyperglycemia, hypertension) if used extensively. Assess fetal growth via ultrasound if prolonged high-potency use occurs. No specific monitoring required for brief, limited applications. |
| Fertility Effects | No known effects on fertility in humans from topical corticosteroids. Animal studies show no impairment at low doses. |
| Clinical Pearls |
| Cordran SP (flurandrenolide) is a high-potency topical corticosteroid. Use for short-term treatment of corticosteroid-responsive dermatoses. Avoid use on face, groin, or axillae due to risk of atrophy. Do not use with occlusive dressings unless directed. Limit treatment to 2 weeks continuous use and no more than 50 g/week to reduce systemic absorption. Monitor for signs of HPA axis suppression, especially in children or with extensive use. |
| Patient Advice | Apply a thin film to the affected area and rub in gently. Do not use on broken skin or near eyes. · Do not bandage, cover, or wrap the treated area unless instructed by your doctor. · Avoid using this medication for longer than prescribed, usually no more than 2 weeks. · Do not use on the face, underarms, or groin without medical advice. · Wash hands after application, unless treating hands. · Inform your doctor if you are pregnant, breastfeeding, or planning to become pregnant. · Avoid using other skin products, including cosmetics or sunscreens, on the treated area without consulting your doctor. |